최신 시험


EudraCT Number: 2022-003056-14 Sponsor Protocol Number: VTX958-203 Start Date: 2023-05-03
Sponsor Name: Ventyx Biosciences, Inc
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Patients with Active Psoriatic Arthritis
Medical condition: Active Psoriatic Arthritis
Disease: Version SOC Term Classification Code Term Level
21.0 100000004859 10037160 Psoriatic arthritis LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) BG (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-004411-11 Sponsor Protocol Number: NeoTreme Start Date: 2023-05-03
Sponsor Name: University Hospital Schleswig-Holstein, Campus Lübeck
Full Title: Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme)
Medical condition: Intrahepatic cholangiocarcinoma
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003452-14 Sponsor Protocol Number: SBC007C401 Start Date: 2023-05-02
Sponsor Name: Berlin Cures GmbH
Full Title: A prospective, double-blind, randomised, parallel group, placebo controlled, multicentre, Phase II study to investigate the efficacy, GPCR autoantibody neutralising effect, safety, and tolerability...
Medical condition: long Covid
Disease: Version SOC Term Classification Code Term Level
25.1 10021881 - Infections and infestations 10087832 COVID-19 rebound LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing) FI (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003532-73 Sponsor Protocol Number: ADVANCE-AD04-001 Start Date: 2023-05-02
Sponsor Name: ADvantage Therapeutics GmbH
Full Title: A Phase 2b, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients with Early Alzheimer’s Disease - ADVANCE
Medical condition: early Alzheimer’s disease
Disease: Version SOC Term Classification Code Term Level
20.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: SK (Ongoing) BG (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-005551-36 Sponsor Protocol Number: NL79416.018.21 Start Date: 2023-05-01
Sponsor Name: Amsterdam University Medical Center, AMC
Full Title: Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock from Acute Myocardial Infarction: A Multicenter Randomized...
Medical condition: Myocardial infarction related cardiogenic shock
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DK (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2022-003866-19 Sponsor Protocol Number: 83336 Start Date: 2023-05-01
Sponsor Name: Amsterdam UMC location AMC
Full Title: The effect of low-dose rhythmic 17-β-estradiol administration on bone turnover in postmenopausal women
Medical condition: Osteoporosis prevention
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003004-33 Sponsor Protocol Number: AR-DEX-22-01 Start Date: 2023-04-26
Sponsor Name: Areteia Therapeutics, Inc.
Full Title: A randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe ...
Medical condition: Severe Eosinophilic Asthma
Disease: Version SOC Term Classification Code Term Level
21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10068462 Eosinophilic asthma LLT
Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
Trial protocol: BG (Ongoing) PL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-000365-41 Sponsor Protocol Number: CNTO1959UCO3004 Start Date: 2023-04-26
Sponsor Name: Janssen-Cilag International NV
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Mode...
Medical condition: Moderately to Severely Active Ulcerative Colitis
Disease: Version SOC Term Classification Code Term Level
20.1 100000004856 10045365 Ulcerative colitis LLT
Population Age: Adults Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing) PL (Ongoing) CZ (Ongoing) HU (Ongoing) BG (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-001793-36 Sponsor Protocol Number: GTX-102-001 Start Date: 2023-04-26
Sponsor Name: Ultragenyx Pharmaceutical Inc.
Full Title: A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)
Medical condition: Angelman Syndrome
Disease: Version SOC Term Classification Code Term Level
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing) FR (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-005099-21 Sponsor Protocol Number: MER-XMT-1536-3 Start Date: 2023-04-25
Sponsor Name: Mersana Therapeutics, Inc.
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensiti...
Medical condition: Recurrent, Platinum-Sensitive Ovarian Cancer
Disease: Version SOC Term Classification Code Term Level
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
Population Age: Adults, Elderly Gender: Female
Trial protocol: FR (Ongoing) NO (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) IT (Ongoing) SE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) NL (Completed)
Trial results: (No results available)
3